BECTON DICKINSON & CO
BDXNYSE · SIC 3841
$158.17
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↑ +15.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$44.4B
Enterprise Value
$60.9B
P/E
40.1
P/S
2.0
P/B
1.8
EV/EBITDA
12.5
PEG
—
FCF Yield
—
Dividend Yield
2.6%
Revenue (TTM)
$22.2B
Net Income (TTM)
$1.1B
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
10.8%
Net Margin
5.1%
ROE
4.7%
ROIC
5.1%
Debt / Equity
0.7
Net Cash
-$16.5B
Return 1Y
+14.0%
Company profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis cathetters, vascular care and preparation products, needle-free IV connectors and extensions sets, syringes, pen needles, and other products for diabetes. Its Life Sciences segment provides specimen and blood collection products; other surgical products.
- CEO
- Thomas E. Polen
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 77,000
- Headquarters
- New Jersey
- Website
- bd.com
Management & directors
- Muhsin BilalEVP & President Connected Care
- Feld MichaelEVP, CRO & Pres. Life Sciences
- Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm
- Menziuso PeterEVP and President, BDI
- Polen Thomas E JrChairman, CEO and President
- Roque VitorEVP & Chief Financial Officer
- Neal Shana CarolEVP and Chief People Officer
- Minnix LaneshaEVP and General Counsel
- Spikner Pamela L.SVPController & Chief Acct Off
- Shan DavidEVP and Chief ISC Officer
- Byrd RichardEVP & President Interventional
- Delorefice ChristopherEVP & Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-06
BDX Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$4.7B↑ +5.2%
Diluted EPS-$1.11↓ -203.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $16.1B | $19.1B | $18.9B | $19.4B | $20.2B | $21.8B |
| Gross profit | $7.6B | — | — | — | — | — |
| Operating income | $912.0M | $2.3B | $2.3B | $2.1B | $2.4B | $2.6B |
| Net income | $874.0M | $2.1B | $1.8B | $1.5B | $1.7B | $1.7B |
| Diluted EPS | $2.71 | $6.85 | $5.88 | $4.94 | $5.86 | $5.82 |
| Operating cash flow | $3.5B | $4.6B | — | — | — | — |
| Free cash flow | $2.8B | $3.5B | — | — | — | — |
| Gross margin | 47.1% | — | — | — | — | — |
| Operating margin | 5.7% | 11.8% | 12.1% | 10.9% | 11.9% | 11.8% |
| Net margin | 5.4% | 10.9% | 9.4% | 7.7% | 8.4% | 7.7% |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0B | $5.4B | $5.2B | $4.5B | $5.5B | $6.7B | $5.3B | $4.7B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $602.0M | $622.0M | $453.0M | $383.0M | $882.0M | $861.0M | $552.0M | $93.0M |
| Net income | $487.0M | $400.0M | $303.0M | $308.0M | $574.0M | $493.0M | $382.0M | -$311.0M |
| Diluted EPS | $1.68 | $1.37 | $1.04 | $1.07 | $2.00 | $1.71 | $1.34 | -$1.11 |
| Operating cash flow | — | — | $693.0M | — | — | — | $657.0M | — |
| Free cash flow | — | — | $588.0M | — | — | — | $549.0M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 12.1% | 11.4% | 8.8% | 8.5% | 16.0% | 12.9% | 10.5% | 2.0% |
| Net margin | 9.8% | 7.4% | 5.9% | 6.9% | 10.4% | 7.4% | 7.3% | -6.6% |
Company news
Jul 15, 2026
Jul 9, 2026
- 11d agoBD to Announce Financial Results for its Third Quarter of Fiscal 2026finance.yahoo.com
- 11d agoThe Wide Chasm Priced Into Boston Scientific Stocktrefis.com
- 11d agoBecton Dickinson (BDX) Stock Trades At A Discount On Cash Flow And Earningsfinance.yahoo.com
- 11d agoBecton Dickinson (BDX) Joins New Russell Indexes, Is The Stock Below Fair Value?finance.yahoo.com
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Muhsin Bilal· EVP & President Connected Care | Tax withholding | 1,935 | $0.00 | $0.00 | filing |
| 2026-07-01 | Muhsin Bilal· EVP & President Connected Care | Award | 14,342 | $0.00 | $0.00 | filing |
| 2026-06-26 | Feld Michael· EVP, Chief Revenue Officer | Sale | 75 | $152.80 | $11,460.00 | filing |
| 2026-06-24 | Garrison Michael David· EVP & Pres Med.Essntl&BioPharm | Sale | 1,100 | $145.66 | $160,226.00 | filing |
| 2026-06-10 | Garrison Michael David· EVP & Pres Med.Essntl&BioPharm | Sale | 1,100 | $151.48 | $166,628.00 | filing |
| 2026-06-01 | Polen Thomas E Jr· Chairman, CEO and President | D | 17,445 | $146.15 | $2.5M | filing |
| 2026-06-01 | Polen Thomas E Jr· Chairman, CEO and President | Option exercise | 20,209 | $126.16 | $2.5M | filing |
| 2026-06-01 | Polen Thomas E Jr· Chairman, CEO and President | Sale | 2,764 | $146.35 | $404,511.40 | filing |
| 2026-06-01 | Menziuso Peter· EVP and President, BDI | Award | 14,258 | $0.00 | $0.00 | filing |
| 2026-05-26 | Feld Michael· EVP, Chief Revenue Officer | Sale | 75 | $147.35 | $11,051.25 | filing |
| 2026-05-07 | Roque Vitor· EVP & Chief Financial Officer | Award | 1,721 | $0.00 | $0.00 | filing |
| 2026-04-27 | Feld Michael· EVP, Chief Revenue Officer | Sale | 74 | $151.94 | $11,243.56 | filing |
| 2026-04-06 | Neal Shana Carol· EVP and Chief People Officer | Tax withholding | 1,146 | $0.00 | $0.00 | filing |
| 2026-03-26 | Feld Michael· EVP, Chief Revenue Officer | Sale | 75 | $156.83 | $11,762.25 | filing |
| 2026-03-16 | Minnix Lanesha· EVP and General Counsel | Award | 7,492 | $0.00 | $0.00 | filing |
| 2026-03-02 | Roque Vitor· Interim CFO | Award | 931 | $0.00 | $0.00 | filing |
| 2026-03-02 | Spikner Pamela L.· SVP Controller & CAO | Award | 931 | $0.00 | $0.00 | filing |
| 2026-02-26 | Feld Michael· EVP, Chief Revenue Officer | Sale | 75 | $181.84 | $13,638.00 | filing |
| 2026-02-18 | SCOTT BERTRAM L | Sale | 953 | $182.61 | $174,027.33 | filing |
| 2026-02-09 | BECTON DICKINSON & CO | J | 284,771,350 | — | — | filing |
| 2026-01-27 | Henderson Jeffrey William | Award | 1,098 | $0.00 | $0.00 | filing |
| 2026-01-27 | ECKERT R ANDREW | Award | 1,098 | $0.00 | $0.00 | filing |
| 2026-01-27 | Byington Carrie L | Award | 1,098 | $0.00 | $0.00 | filing |
| 2026-01-27 | HAYES GREGORY | Award | 1,098 | $0.00 | $0.00 | filing |
| 2026-01-27 | Brown William M | Award | 1,098 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.